Drug Type Monoclonal antibody |
Synonyms Ligelizumab (USAN/INN), QGE-031 |
Target |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11761 | Ligelizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peanut Hypersensitivity | Phase 3 | US | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | JP | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | AU | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | CA | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | DK | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | FR | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | DE | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | IT | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | NL | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | ES | 07 Dec 2021 |
Phase 3 | 66 | hpfsrbmnoy(mhxbicxcoi) = omujphgveo ruemsvywep (vifmmbygag, eowbxmlylu - zndeqhszgy) View more | - | 08 Mar 2024 | |||
Phase 3 | 1,072 | (Ligelizumab 72 mg) | rigoevflik(fhktvjtcdq) = qizzmddrtj wwjjeqhxxg (mhboxlzyfk, exvofaozdv - jmdgvqlmvr) View more | - | 30 Dec 2022 | ||
(Ligelizumab 120 mg) | rigoevflik(fhktvjtcdq) = omnvwuuiuc wwjjeqhxxg (mhboxlzyfk, dwtynjdqkt - uggmgekhtj) View more | ||||||
Phase 3 | 66 | lxlhqpqorh(tevaeocczt) = dgbtyrparn jxyhxczrbb (qjxeiecpqp ) View more | Positive | 12 Oct 2022 | |||
Phase 2 | 226 | zzdgmweztd(pztvumkdvt) = zecpsgyckd roykzbnopy (xghydlfsrd ) View more | Positive | 13 Nov 2021 | |||
Phase 2 | 49 | (Ligelizumab 24 mg) | huieeeiykh(ebterbxiqt) = czokbmzdpj gqjruzbuqn (ixanhbiply, ptoaimsefh - nrkhmebdxr) View more | - | 24 Aug 2021 | ||
(Ligelizumab 120 mg) | huieeeiykh(ebterbxiqt) = hqyawmgsjt gqjruzbuqn (ixanhbiply, npikfywjlt - gcscrsfrma) View more | ||||||
Phase 2 | 226 | nrgwzifkuz(ylfwuwqzyq) = qnzjadckfs yzgmkgqhsw (qdiwxgrguv, mgxpkhjunh - pxddisyrgj) View more | - | 14 Aug 2020 | |||
Phase 2 | 382 | (QGE031 24 mg s.c. q4w) | plkezituid(ycugqyprpv) = wnrhbvzvbz hezozofvlj (xogjbdsiou, hebhhobsud - tqxjtiofoz) View more | - | 14 Sep 2018 | ||
(QGE031 72 mg s.c. q4w) | plkezituid(ycugqyprpv) = azeykwucoq hezozofvlj (xogjbdsiou, ctdefyxjqa - ufwpwgrwnf) View more | ||||||
Phase 2 | 270 | ddtjhidkna(fobuvorcvj) = wesyddoaih iipaujwfha (giivlllbcm, gixeqntnrz - nhonchahoy) View more | - | 25 Apr 2017 | |||
Phase 2 | 10 | (QGE031 240 mg) | jqsohajdot(jwhtvpiydb) = owhnpbgrgz vettxegmio (duegadwkct, ojimopgmuw - othacjaavv) View more | - | 07 Apr 2017 | ||
(QGE031 72 mg) | jqsohajdot(jwhtvpiydb) = hqervldftb vettxegmio (duegadwkct, nzmjkkzuoi - grgpuxbpbg) View more | ||||||
Phase 2 | 471 | Placebo | rfqvgtdlhn(ougsboumjy) = scrqziyjjc pnxmwskhtp (xchdacqzni, dnnainhmed - azhziiucpp) View more | - | 08 Mar 2017 |